To access this material please log in or register

Register Authorize

Case reports of hypertrophic cardiomyopathy in dilated phase

Bogdanov D. V., Shaposhnik I. I.

Keywords: hypertrophic cardiomyopathy, dilatation, heart failure

DOI: 10.18087/rhfj.2013.4.1802

Background. In some cases, hypertrophic cardiomyopathy (HCMP) is associated with pronounced cavity dilatation and reduced EF. This condition is understudied. Aim. Evaluating peculiarities of HCMP transformation into dilated cardiomyopathy during prolonged follow-up. Materials and methods. 152 patients with HCMP; major study methods: ECG, 24‑h ECG monitoring, echoCG. Results. During prolonged follow-up of 152 patients with HCMP, 8 patients (5.3 %) had significant LV cavity dilatation with EF <45 %. A cause for this change is not quite clear. Formally, such changes are consistent with dilated cardiomyopathy (DCMP). However, differences between the final HCMP stage and DCMP were found. The matter concerns just the dilated HCMP phase which has some manifestations similar to DCMP. Conclusion. The dilating transformation was observed in 5.3 % of patients. The HCMP progression took place during impairment of not only diastolic but also systolic myocardial function in patients with greater initial thickness of the myocardium as compared to patients with stable disease.
  1. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF / AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardio­logy Foundation / American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58 (25):e212–260.
  2. Шапошник И. И., Шапошник О. Д. Развитие признаков дилатационной кардиомиопатии у больных необструктивной гипертрофической кардиомиопатией. Тер. Архив. 1992;64 (11):125–126.
  3. Jurynec J. Hypertrophic Cardiomyopathy: A Review of Etiology and Treatment. J Cardiovasc Nurs. 2007;22 (1):65–73.
  4. Maron BJ, Casey SA, Haas TS et al. Hypertrophic cardiomyopathy with longevity to 90 years or older. Am J Cardiol. 2012;109 (9):1341–1347.
  5. Christiaans I, van Engelen K, van Langen IM et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systema­tic review of clinical risk markers. Europace. 2010;12 (3):313–321.
  6. Шапошник И. И., Богданов Д. В. Гипертрофическая кардиомиопатия. – М:. Медпрактика-М, 2008. – c.19–20.
  7. Vaglio JC Jr, Ommen SR, Nishimura RA et al. Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction. Am Heart J. 2008;156 (2):342–347.
  8. Мордяшова С. В. Применение 6‑минутного теста ходьбы у больных гипертрофической кардиомиопатией. Международный медицинский журнал (Харьков). 2009;15 (2):54–58.
  9. Тихомирова Е. А., Куприянова О. О., Басаргина Е. Н. Динамика показателей сердечно-сосудистой системы на фоне применения бета-адреноблокаторов у детей с обструктивной формой гипертрофической кардиомиопатии. Педиатрическая фармакология. 2007;4 (5):64–68.
  10. Якушин С. С., Филиппов Е. В. Гипертрофическая кардиомиопатия: результаты пятилетнего наблюдения. Болезни сердца и сосудов. 2006;2 (2):38–41.
  11. Беленков Ю. Н., Привалова Е. В., Каплунова В. Ю. и др. Гипертрофическая кардиомиопатия, особенности течения при длительном наблюдении. Терапевтический архив. 2008;80 (8):18–25.
  12. Frustaci A, Verardo R, Caldarulo M et al. Myocardial inflammation in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J. 2007;28 (6):733–740.
  13. Biagini E, Pazzi C, Rosmini S et al. An unusual case of familial hypertrophic cardiomyopathy with left ventricular systolic dysfunction: a still unsolved diagnosis. Сardiogenetics. 2012;2 (1):43–47.
  14. Efthimiadis GK, Giannakoulas G, Parharidou DG et al. Prevalence of end-stage phase in an unselected regional population with hypertrophic cardiomyopathy. Am J Cardiol. 2006;98 (9):1269–1272.
  15. Крылова Н. С., Авдеева Е. В., Потешкина Н. Г. Хроническая сердечная недостаточность у больных гипертрофической кардиомиопатией. Российский кардиологический журнал. 2011;15 (2):26–31.
  16. Biagini E, Pedone C, Coccolo F et al. End-stage evolution of hypertrophic cardiomyopathy: prevalence, incidence and incremental risk. Eur Heart J. 2003;24 (Suppl): 559.
  17. Garcia-Pavia P, Vázquez ME, Segovia J et al. Genetic basis of end-stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2011;13 (11):1193–1201.
  18. Ramaraj R. Hypertrophic Cardiomyopathy: Etiology, Diagnosis, and Treatment. Cardiol Rev. 2008;16 (4):172–180.
  19. Hamada T, Kubo T, Kitaoka H et al. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy. Clin Cardiol. 2010;33 (7):E24–28.
  20. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113 (14):1807–1816.
Bogdanov D. V., Shaposhnik I. I. Case reports of hypertrophic cardiomyopathy in dilated phase. Russian Heart Failure Journal. 2013;14 (4):206-209

To access this material please log in or register

Register Authorize
Ru En